Table 1. Demographic and clinico-pathological characteristics of the study cohort.
| Prognostic variable & categories | Cohort 1 (n = 221) |
Cohort 2 (n = 182) |
Cohort 3 (n = 140) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FOXO1 positive (n=39) | FOXO1 negative (n = 101) |
Total | ||||||||||||||
| PAX3 (n = 27) | PAX7 (n = 12) | |||||||||||||||
| Age groups | n | % | n | % | n | % | n | % | n | % | n | % | ||||
| <10 years | 174 | 78.70 | 148 | 81.30 | 17 | 63.00 | 11 | 91.60 | 87 | 86.10 | 115 | 82.20 | ||||
| ≥10 years | 47 | 21.30 | 34 | 18.70 | 10 | 37.00 | 01 | 8.40 | 14 | 13.90 | 25 | 17.80 | ||||
| Group | ||||||||||||||||
| Group 1 | 11 | 5.00 | 11 | 6.00 | 03 | 11.10 | - | - | 05 | 4.95 | 08 | 5.70 | ||||
| Group 2 | 05 | 2.30 | 05 | 2.70 | 01 | 3.80 | - | - | 02 | 2.00 | 03 | 2.10 | ||||
| Group 3 | 166 | 75.10 | 166 | 91.20 | 23 | 85.10 | 12 | 100 | 94 | 93.05 | 129 | 92.10 | ||||
| Group 4 | 39 | 17.60 | NA | NA | ||||||||||||
| Histology | ||||||||||||||||
| Embryonal | 142 | 64.30 | 118 | 64.80 | 07 | 26.00 | 07 | 58.34 | 71 | 70.30 | 85 | 60.70 | ||||
| Alveolar | 67 | 30.30 | 55 | 30.20 | 20 | 74.00 | 05 | 41.66 | 24 | 23.70 | 49 | 35.00 | ||||
| Others | 12 | 5.40 | 09 | 4.90 | - | - | - | - | 06 | 6.00 | 06 | 4.30 | ||||
| Tumour size | ||||||||||||||||
| <5 cm | 90 | 40.70 | 80 | 44.00 | 16 | 59.20 | 04 | 33.33 | 46 | 45.50 | 66 | 47.10 | ||||
| 5–10 cm | 97 | 43.90 | 77 | 42.30 | 09 | 33.40 | 04 | 33.33 | 44 | 43.50 | 57 | 40.80 | ||||
| >10 cm | 31 | 14.10 | 23 | 12.60 | 02 | 7.40 | 04 | 33.34 | 11 | 11.00 | 17 | 12.10 | ||||
| Insufficient dataa | 03 | 1.30 | 02 | 1.10 | NA | |||||||||||
| Nodal status | ||||||||||||||||
| N0 | 129 | 58.40 | 109 | 59.90 | 16 | 59.20 | 04 | 33.33 | 67 | 66.30 | 87 | 62.10 | ||||
| N1 | 90 | 40.70 | 71 | 39.00 | 11 | 40.80 | 08 | 66.67 | 34 | 33.70 | 53 | 37.90 | ||||
| Insufficient dataa | 02 | 0.90 | 02 | 1.10 | NA | |||||||||||
| Site | ||||||||||||||||
| Favourable | 55 | 24.90 | 49 | 26.90 | 09 | 33.40 | 03 | 25.00 | 30 | 30.00 | 42 | 30.00 | ||||
| Unfavourable | 166 | 75.10 | 133 | 73.10 | 18 | 66.60 | 09 | 75.00 | 71 | 70.00 | 98 | 70.00 | ||||
| As per organ of origin | ||||||||||||||||
| Orbit | 12 | 5.40 | 12 | 6.60 | 01 | 3.80 | 01 | 8.30 | 09 | 8.90 | 11 | 7.90 | ||||
| Non-BPK genitourinary | 20 | 9.00 | 15 | 8.20 | 03 | 11.10 | - | - | 07 | 6.90 | 10 | 7.10 | ||||
| Non-PM head & neck | 22 | 10.00 | 21 | 11.50 | 05 | 18.50 | 02 | 16.70 | 13 | 12.90 | 20 | 14.30 | ||||
| PM head & neck | 65 | 29.40 | 56 | 30.80 | 10 | 37.00 | 01 | 8.30 | 30 | 29.70 | 41 | 29.30 | ||||
| Genitourinary | 18 | 8.10 | 16 | 8.80 | - | - | - | - | 08 | 8.00 | 08 | 5.70 | ||||
| Extremity | 44 | 19.90 | 34 | 18.70 | 06 | 22.20 | 08 | 66.70 | 16 | 15.80 | 30 | 21.40 | ||||
| Others | 40 | 18.10 | 28 | 15.40 | 02 | 7.40 | - | - | 18 | 17.80 | 20 | 14.30 | ||||
| COG risk | ||||||||||||||||
| LR (A) | 20 | 9.00 | 20 | 11.00 | 03 | 11.10 | 01 | 8.40 | 11 | 10.90 | 15 | 10.70 | ||||
| LR (B) | 16 | 7.20 | 16 | 8.80 | 01 | 3.80 | 01 | 8.30 | 12 | 11.90 | 14 | 10.00 | ||||
| IR | 146 | 66.10 | 146 | 80.20 | 23 | 85.10 | 10 | 83.30 | 78 | 77.20 | 111 | 79.30 | ||||
| High risk | 39 | 17.60 | NA | NA | ||||||||||||
| Revised riskb | ||||||||||||||||
| LR | 11 | 5.00 | 11 | 6.00 | - | - | - | - | 11 | 10.90 | 11 | 7.10 | ||||
| IR | 166 | 75.10 | 166 | 91.20 | 27 | 100 | 12 | 100 | 90 | 89.10 | 129 | 92.90 | ||||
| High risk | 39 | 17.60 | NA | |||||||||||||
| Insufficient datac | 05 | 2.30 | 05 | 2.80 | ||||||||||||
| FOXO1 fusion | ||||||||||||||||
| PAX3 positive | 33 | 14.90 | 27 | 14.80 | ||||||||||||
| PAX7 positive | 14 | 6.30 | 12 | 6.60 | ||||||||||||
| Both negative | 129 | 58.40 | 101 | 55.50 | ||||||||||||
| Insufficient data | 45 | 20.40 | 42 | 23.10 | ||||||||||||
a
Data not available
b
As per the ARST 1431 risk stratification
c
Molecular data not available in 5 LR (A) patients
NA, Not applicable; PM, Parameningeal; BPK, Bladder/prostate/kidney